Results 61 to 70 of about 15,930 (153)

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source

Association Between BMI and the Efficacy and Safety of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer: A Multicenter Retrospective Propensity Score Matched Cohort Study (CAMELIA)

MedComm – Oncology, Volume 5, Issue 4, December 2026.
This multicenter real‐world study showed that higher BMI (≥ 25 kg/m2) was independently associated with improved PFS in patients with HR+/HER2− advanced breast cancer receiving CDK4/6 inhibitors. Safety outcomes were comparable between BMI groups, and the findings were consistent across alternative BMI thresholds, suggesting the potential prognostic ...
Min Tian, Yijia Hua, Qian Liu, Nan Jin, Xinyu Wu, Kun Wang, Min Yan, Tao Sun, Chunfang Hao, Yanxia Zhao, Wei Li, Xiang Huang, Yongmei Yin   +12 more
wiley   +1 more source

De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer

International Journal of Cancer, Volume 159, Issue 10, Page 2393-2402, 15 November 2026.
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley   +1 more source

Pan‐Cancer Landscape of TMEM9 With Experimental Validation in Head and Neck Squamous Cell Carcinoma

The Journal of Gene Medicine, Volume 28, Issue 11, November 2026.
Transmembrane protein 9 (TMEM9) was investigated across cancers using public transcriptomic, clinical, genomic, and immune datasets, followed by functional validation in head and neck squamous cell carcinoma (HNSC). TMEM9 showed cancer‐dependent expression, diagnostic discrimination, prognostic associations, and relationships with immune infiltration ...
Mi Wang, Shangyan Ying, Chunyan Weng, Youfeng Li   +3 more
wiley   +1 more source

Interpretable Drug–Target Prediction via Geometric Alignment: A Linear Alternative to Deep Architectural Complexity

Molecular Informatics, Volume 45, Issue 11, November 2026.
The Multi‐View Linear Manifold (MVLM) aligns frozen chemical and protein language model embeddings in a shared geometric space using two linear projections. Binding is scored by a single dot product. MVLM achieves state‐of‐the‐art drug–target interaction prediction on KIBA, performs competitively on Davis, and recovers kinase phylogenetic structure ...
Aashutosh Ghimire, Chris Alvin, Adam Bess, Supratik Mukhopadhyay   +3 more
wiley   +1 more source

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Breast Cancer Research, 2019
Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens.
Lorenzo Rossi, Chiara Biagioni, Amelia McCartney, Ilenia Migliaccio, Giuseppe Curigliano, Giuseppina Sanna, Erica Moretti, Alessandro M. Minisini, Saverio Cinieri, Carlo Tondini, Grazia Arpino, Antonio Bernardo, Angelo Martignetti, Emanuela Risi, Marta Pestrin, Luca Boni, Matteo Benelli, Laura Biganzoli, Angelo Di Leo, Luca Malorni   +19 more
doaj   +1 more source

Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell‐cycle, MAPK, and PI3K pathways

The Journal of Pathology, Volume 270, Issue 3, Page 380-395, November 2026.
Abstract Mucosal melanomas (MMs) are rare, aggressive cancers with poor outcomes and limited response to standard therapies. A significant knowledge gap exists regarding their genomic landscape and corresponding druggable targets. This study explores this issue through a multi‐omic analysis, including whole exome‐, RNA‐, and targeted sequencing, of ...
Matilde Monti, Martina Brigida Romanello, Luca Agnelli, Matteo Orlandi, Luca Bertoli, Sara Picinoli, Irene Pezzali, Giulio Eugenio Mandelli, Daniela Medicina, Giovanni Ribaudo, Adele Busico, Elena Conca, Vilma Pellegrini, Piera Balzarini, Daniele Gallucci, Anna Di Matteo, Davide Lombardi, Claudia Ghigna, Giancarlo Pruneri, Alessandra Gianoncelli, Marzia Rossato, William Vermi   +21 more
wiley   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling‐Veninga, Katja Taxis, Frank G. A. Jansman   +5 more
wiley   +1 more source

A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents

ChemMedChem, Volume 21, Issue 20, 28 October 2026.
This perspective efficiently summarizes the development of lysine acetyltransferase (KAT) inhibitors as anticancer agents, and the most clinically advanced KAT6A inhibitor, prifetrastat, entered Phase III clinical trials in 2025. KAT6A structural biology and structure activity relationships for acylsulfonylhydrazides, [1,2,4]thiadiazines, and ...
Rochelle Woodland, Adi Suwandi, Awgichew Behaile Teklemariam, Nidhish Francis, Li Li, Kenneth A. Chinkwo, Jonathan B. Baell, David J. Leaver   +7 more
wiley   +1 more source

Quercetin inhibits the epithelial-mesenchymal transition and reverses CDK4/6 inhibitor resistance in breast cancer by regulating circHIAT1/miR-19a-3p/CADM2 axis.

PLoS ONE
Breast cancer (BC) cells have a high risk of metastasis due to epithelial-mesenchymal transition (EMT). Palbociclib (CDK4/6 inhibitor) is an approved drug for BC treatment.
Xiaogang Li, Chao Niu, Guoqiang Yi, Yuan Zhang, Wendi Jin, Zhiping Zhang, Wanfu Zhang, Bo Li   +7 more
doaj   +1 more source